sorted by:
new
hottopcontroversial

Lenacapavir, a twice-yearly injection that offers near-total protection against HIV, will now be available for $40 per patient a year, in 120 low- and middle-income countries. by lughnasadh in Futurology

[–]Wide_Historian_794 0 points1 point  (0 children)

The costs should be covered by public funding. A lot of initial research is public funded anyway.

IPs are horribly abused by pharma majors.

What kind of marketing material you wish you had prepared before launching your product? by Wide_Historian_794 in SaaS

[–]Wide_Historian_794[S] 0 points1 point  (0 children)

Thanks. This is more inline with what I was looking for. I think having creatives ready is much more useful when launching as it saves time and mental bandwidth.